<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924686</url>
  </required_header>
  <id_info>
    <org_study_id>ZhujiangH-1</org_study_id>
    <nct_id>NCT04924686</nct_id>
  </id_info>
  <brief_title>Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases</brief_title>
  <official_title>A Bacterial Bi-functional Peptidoglycan Hydrolase Sheds NOD2 Ligands to Regulate Gut Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To&#xD;
      figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the&#xD;
      change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic&#xD;
      cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have shown that NOD2 gene mutants were associated with the Crohn's disease&#xD;
      (CD), colorectal cancer (CRC) and many other diseases, suggesting the critical role of NOD2&#xD;
      signaling in human physiology and pathogenethesis. However, whether decreased NOD2 ligands&#xD;
      also contributed to these diseases is unknown. In this study, the investigators plan to&#xD;
      evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC,&#xD;
      atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ). For each&#xD;
      of the patient, a sex- and age- matched control were chosen. Both the targeted metabolomics&#xD;
      (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters were&#xD;
      used to test NOD2 ligands in the fecal and plasma samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NOD2 ligands in fecal and plasma</measure>
    <time_frame>baseline</time_frame>
    <description>detected using targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <description>The fecal and plasma were collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis</arm_group_label>
    <description>The fecal and plasma were collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes mellitus, type 2</arm_group_label>
    <description>The fecal and plasma were collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atherosclerotic cardiovascular disease</arm_group_label>
    <description>The fecal and plasma were collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <description>The fecal and plasma were collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational studies, no intervention</intervention_name>
    <description>Observational studies, no intervention</description>
    <arm_group_label>Atherosclerotic cardiovascular disease</arm_group_label>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_label>Diabetes mellitus, type 2</arm_group_label>
    <arm_group_label>Ulcerative colitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal, Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients with IBD, CRC, ACVD or DM2 hospitalized in Zhujiang hospital will be&#xD;
        eligible to be enrolled. Also, their age- and sex- matched healthy controls making a&#xD;
        physical examination in Zhujiang hospital will be eligible to be enrolled&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females at least 18-70 years old.&#xD;
&#xD;
          2. Patient able to give informed consent.&#xD;
&#xD;
          3. Patient with biopsy-proven CRC&#xD;
&#xD;
          4. Patient with biopsy-proven Crohn's disease (CD) or ulcerative colitis(UC), in the&#xD;
             active phase.&#xD;
&#xD;
          5. patients with clinical diagnosed DM2&#xD;
&#xD;
          6. patients with ACVD:coronary angiography more than 50% stenosis in single or multiple&#xD;
             vessels.&#xD;
&#xD;
          7. The age- and sex- matched health controls for each patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1.Use antibiotics or probiotics within the last 2 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongwei Zhou, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhujiang Hospital, Guangzhou, Guangdong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Gao, PHD</last_name>
    <phone>15625043043</phone>
    <phone_ext>86</phone_ext>
    <email>994856235@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang Dong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Hongwei, Professor</last_name>
      <phone>18688489622</phone>
      <email>hzhou@smu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol. 2014 Jan;14(1):9-23. doi: 10.1038/nri3565. Epub 2013 Dec 13. Review. Erratum in: Nat Rev Immunol. 2014 Feb;14(2):131.</citation>
    <PMID>24336102</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhujiang Hospital</investigator_affiliation>
    <investigator_full_name>Hongwei Zhou</investigator_full_name>
    <investigator_title>Proffessor</investigator_title>
  </responsible_party>
  <keyword>NOD2 ligands</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

